Larimar Therapeutics
Nicholas Cooke, MPH, is an experienced clinical research professional currently serving as a TMF QC Reviewer at Larimar Therapeutics Inc. since February 2024. Previous roles include Clinical Trial Associate at Aclaris Therapeutics, Inc. and Clinical Research Associate 1 at ICON plc, where responsibilities involved monitoring clinical trials for compliance with protocols and regulations. Nicholas also has a background as a Research Assistant at Penn Medicine and a Clinical Research Data Specialist at Fox Chase Cancer Center, supporting various oncology trials. Additional experience includes supervising contact tracers during the COVID-19 pandemic and conducting research at the American Association for Cancer Research. Nicholas holds a Master's degree in Public Health and a Bachelor of Science in Public Health from Temple University.
Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. The company’s lead compound, CTI-1601, is currently being evaluated in the Phase 1 clinical program as a potential treatment for Friedreich’s ataxia, a rare and progressive genetic disease.